U.S., Sept. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07177339) titled 'eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation' on Sept. 15.
Brief Summary: Depemokimab is being developed as a treatment for individuals with moderate to severe Chronic Obstructive Pulmonary Disorder (COPD). The aim of this study is to assess the efficacy and safety of early initiation of depemokimab as an add-on medicine in participants with moderate to severe COPD with type 2 inflammation.
Study Start Date: Nov. 17
Study Type: INTERVENTIONAL
Condition:
Pulmonary Disease, Chronic Obstructive
Intervention:
DRUG: Depemokimab...